Navigation Links
Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD
Date:9/22/2010

p>

23%week 6

8%

23%

19%week 12

2%

19%

19%Mean improvement in patient-reported QOL
week 8 vs. baseline

21%

34%

13%* p<0.001 relative to baseline"ITCA 650 therapy represents an important advance in the treatment of type 2 diabetes.  For the first time, patients are able to receive all the benefits of a GLP-1 therapy without the need for self-injection," said Robert Henry, M.D., Chief, Section of Diabetes, Endocrinology and Metabolism at the University of California, San Diego. He noted, "Injection has been a significant hurdle for the use of GLP-1 therapies for many patients.  ITCA 650 allows far more patients to benefit from GLP-1 therapy due to better tolerability and ease of administration. We are highly encouraged by improved levels of patient acceptance of ITCA 650, indicating broader use potential."

Summary of Week 24 ResultsAfter initial treatment week 12, patients on the ITCA 650 arms were re-randomized on a 1:1 basis to either continue on the same dose (20 mcg/day or 40 mcg/day) or escalate to higher doses of ITCA 650 (60 mcg/day or 80 mcg/day) for weeks 13 - 24.  Patients on the exenatide injection arm were switched to receive ITCA 650 at a dose of either 40 mcg/day or 60 mcg/day for weeks 13 – 24.

Incremental reductions in HbA1c and weight were observed across all treatment arms at week 24 compared to week 12. Both incremental and aggregate reductions in HbA1c were greatest in the 60 mcg/day and 80 mcg/day dose arms but not measurably different between the two dose arms.  Results of the week 20 quality of life assessment suggest that quality of life improved substantially for patients switching from exenatide injection to ITCA 650 and that the substantial improvement observed among patients initially randomized to ITCA 650 was maintained after transition to higher doses of ITCA 650.ITCA 650 Dose weeks 13 – 24

20 mcg/day


'/>"/>
SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
2. Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... CHESTERBROOK, Pa. , May 24, 2013  Auxilium ... that executive management will participate in the Deutsche Bank ... the Westin Boston Waterfront Hotel.  Mr. Adrian ... scheduled to present an overview of the Company and ... May 29, 2013.   (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ...
(Date:5/24/2013)... , May 24, 2013 ... administration for systemic delivery of therapeutic agents has been ... inhalation drug delivery showing significant promise. The crucial formulation ... a delivery device play a major role in the ... made in the development of new formulation techniques and ...
(Date:5/23/2013)... 23, 2013  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... the 2013 Life Science Firm of the Year by the ... was honored at the TCM,s 25 th Annual Tech ... The Tech Awards Celebration recognizes the leaders and innovators in ... and the surrounding regions. "We ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2
... large, randomized Phase III study of ERBITUX ... neck cancer,meets primary endpoint of improving overall ... /PRNewswire-FirstCall/ -- ImClone,Systems Incorporated and Bristol-Myers Squibb ... III study of ERBITUX(R) (Cetuximab),combined with platinum-based ...
... --,SuperGen Inc. announced today that it will have ... Meeting on April 14-18 in Los Angeles. These ... current oncology,programs including its lead tyrosine kinase inhibitor ... key protein target involved,in cancer cell drug resistance. ...
Cached Medicine Technology:Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 2Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 3Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 4Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 5Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 6Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 7Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 8Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 9SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR 2SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR 3SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR 4
(Date:5/24/2013)... New York, New York (PRWEB) May 24, 2013 ... da Vinci lawsuit involving Intuitive Surgical Inc.’s da ... According to court records, a Washington State Court ... not committed negligence in training a surgeon who performed ... several years later. The patient’s family had alleged ...
(Date:5/24/2013)... to the development of infantile myofibromatosis (IM)a disorder characterized ... tissuemay provide new therapeutic targets, according to researchers from ... findings, published in the American Journal of Human ... this debilitating disease, for which the only current treatment ... IM is an inheritied disorder that develops in infancy ...
(Date:5/24/2013)... 24, 2013 BestSatelliteProviders.com the online ... thousands of consumers compare the features and services ... site recently released the rankings of the best ... available for viewing on their website. , ... According to Adam Matthews, the spokesperson for BestSatelliteProviders.com, ...
(Date:5/24/2013)... -- People with high levels of cadmium in their ... disease than those with lower levels, a new study ... is evidence of long-term exposure to the heavy metal ... the Johns Hopkins researchers explained. They also said ... liver disease but instead suggest an association that requires ...
(Date:5/24/2013)... 6Webs.com has educated thousands of buyers on ... security monitoring provider. The easy to read reviews ... consumers prefer for unbiased and impartial home security reviews. ... leading wireless home security system providers in the nation. ... number of key factors including reliability, technology and equipment. ...
Breaking Medicine News(10 mins):Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 3Health News:Researchers identify first drug targets in childhood genetic tumor disorder 2Health News:Best Rural Internet Service Provider in 2013 by BestSatelliteProviders.com 2Health News:High Cadmium Levels May Raise Risk for Dying From Liver Disease: Study 2Health News:2013 Best Wireless Security System Providers Reported by 6Webs.com 2
... other diseases that affect red blood cells , , THURSDAY, April ... skin, says a new study that showed the skin plays ... and in stimulating kidney production of the hormone erythropoietin (EPO) ... blood cells that carry and deliver oxygen throughout the body. ...
... at National Jewish Medical and Research Center are conducting ... to food. They are feeding peanut- and egg-allergic people ... foods to see if they can induce the participants ... hope these trials will lead to the development of ...
... company selects partner for speech understanding ... ... 17 Heartland Information Services, (http://www.heartlandis.com ), a medical transcription ... which will supply,Heartland with advanced speech recognition and understanding technologies.,The ...
... This release is available in Spanish . , ... and the Biotechnology Institute of the University ... known as elecampe, can be used to obtain inhibitors of neurogenic ... study, supervised by professors Mara del Mar Herrador and ...
... ... Industry Involvement, ... Inc. (http://www.siemens.com/healthcare ) today announced a series of,executive ... healthcare industry organizations., (Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO ), ...
... Healthcare, Trade and the Economy, WASHINGTON, April 17 ... can take part in National Small,Business Week 2008, featuring ... event., These public policy forums will feature leading ... economy:, WHO:, Secretary Michael Leavitt, U.S. Department ...
Cached Medicine News:Health News:Mice Can Sense Oxygen Through Their Skin 2Health News:Researchers evaluating food allergy treatment 2Health News:Heartland Information Services Announces Alliance with M*Modal 2Health News:Heartland Information Services Announces Alliance with M*Modal 3Health News:Scientists obtain anticancer medicines from the elecampe, a wild plant growing in the Mediterranean 2Health News:Siemens Healthcare Executives Recognized With New Industry Leadership Positions 2Health News:Siemens Healthcare Executives Recognized With New Industry Leadership Positions 3Health News:Siemens Healthcare Executives Recognized With New Industry Leadership Positions 4Health News:Siemens Healthcare Executives Recognized With New Industry Leadership Positions 5Health News:Live Webcast of SBA's National Small Business Week Policy Forums Scheduled 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: